Functional Precision Oncology: Testing Cancer Cells to Find the Right Treatment

 

Functional Precision Oncology: Testing Cancer Cells to Find the Right Treatment

Cancer treatment is becoming increasingly personalized. Instead of relying only on the cancer's location or a broad diagnosis, researchers and clinicians are looking for ways to understand the unique biological characteristics of each patient's tumor. Genomic sequencing, biomarkers, liquid biopsy, immunotherapy, and other precision oncology approaches have already changed how cancer is studied and treated.

However, one important question remains:

Can we directly test a patient's cancer cells to determine which treatment is most likely to work?

This is where functional precision oncology is gaining attention.

Functional precision oncology focuses on observing how a patient's actual cancer cells respond to different therapies. Rather than relying exclusively on genomic information to predict treatment response, researchers can use patient-derived tumor cells or related experimental models to test therapeutic sensitivity in the laboratory.

This approach could provide another layer of information for personalized cancer care—particularly when genomic findings alone do not clearly identify the best treatment option.

 

What Is Functional Precision Oncology?

Functional precision oncology is an emerging approach within precision medicine that evaluates how living tumor cells respond to potential treatments.

Traditional precision oncology often begins by analyzing a tumor's molecular characteristics. Tests may identify mutations, gene amplifications, fusions, alterations in DNA repair pathways, or other biomarkers that can help guide treatment selection.

Functional precision oncology asks a complementary question:

"What happens when this patient's cancer cells are actually exposed to different therapies?"

Tumor material obtained from a patient may be processed and studied using laboratory models. Researchers can then investigate responses to selected drugs or drug combinations.

The objective is not simply to identify what mutations are present, but to understand the functional behavior of the tumor.

This creates an important distinction:

Genomic precision medicine:
What molecular alterations does the tumor have?

Functional precision medicine:
How does the tumor behave when exposed to different therapeutic strategies?

Combining these perspectives could potentially provide a more comprehensive picture of cancer biology.

 

Why Functional Testing Matters in Cancer Treatment

Cancer is highly heterogeneous. Even patients diagnosed with the same cancer type may have tumors with very different biological characteristics.

Two patients may have:

• The same cancer diagnosis
• Similar disease stages
• Similar histological characteristics
• Some overlapping genomic alterations

Yet their tumors may respond very differently to the same treatment.

This is one of the major challenges in oncology.

A genomic alteration may suggest that a particular therapy could be useful, but the presence of a biomarker does not always guarantee a meaningful clinical response. Conversely, a tumor without an obvious conventional biomarker may still demonstrate sensitivity to a particular therapeutic approach.

Functional testing attempts to capture some of this complexity by examining actual treatment response at the cellular or model level.

This could become particularly valuable when clinicians face several possible treatment options and need additional evidence to prioritize them.

 

Genomic Precision Oncology vs Functional Precision Oncology

Genomic testing has become a major component of modern precision oncology.

Next-generation sequencing can identify alterations across numerous genes and may reveal clinically actionable biomarkers.

However, cancer biology is more complicated than a list of mutations.

A tumor's behavior can be influenced by:

• Multiple genomic alterations
• Gene expression patterns
• Epigenetic regulation
• Protein signaling
• Tumor heterogeneity
• Cellular interactions
• Tumor microenvironment
• Drug metabolism
• Resistance mechanisms
• Evolution during treatment

Functional precision oncology therefore represents a complementary strategy.

Genomic approach

The tumor is analyzed to determine its molecular profile.

Functional approach

Tumor-derived cells or models are exposed to therapies to investigate treatment response.

Integrated approach

Genomic, transcriptomic, functional, pathological, and clinical information can potentially be combined to generate a more comprehensive treatment strategy.

The future of precision oncology may increasingly involve both molecular information and functional evidence rather than treating them as competing approaches.

 

How Functional Precision Oncology Works

The exact workflow can vary depending on the tumor type, sample availability, laboratory model, and research or clinical setting.

A simplified workflow may involve several stages.

1. Obtaining Tumor Material

The process generally begins with a tumor sample obtained through an appropriate clinical procedure.

Depending on the situation, researchers may work with:

• Surgical tumor tissue
• Biopsy samples
• Metastatic lesions
• Other patient-derived tumor material

The quality and quantity of available tissue can influence whether functional testing is feasible.

 

2. Processing the Sample

The tumor material is processed under laboratory conditions to preserve and study relevant cancer cells.

Researchers may develop experimental models that retain selected characteristics of the original tumor.

These models can vary substantially in complexity.

Some approaches use relatively simple cell cultures, while others attempt to preserve more of the tumor's biological architecture.

 

3. Creating Patient-Derived Models

One important area of functional precision oncology involves patient-derived models.

These may include:

• Patient-derived tumor cell cultures
• Patient-derived organoids
• Tumor explants
• Patient-derived xenografts
• Other experimental systems

Each model has advantages and limitations.

For example, organoid systems can reproduce certain aspects of tumor organization, while xenograft models may provide information about tumor behavior in a living biological environment.

The choice of model depends on the scientific question being investigated.

 

4. Testing Therapeutic Responses

Researchers can expose the experimental tumor model to selected therapies.

Depending on the study, testing may involve:

• Targeted therapies
• Chemotherapy
• Immunotherapy-related strategies
• Combination treatments
• Investigational drugs
• Drug sequencing strategies

The response can then be measured using appropriate laboratory techniques.

Researchers may examine:

• Cell viability
• Cell death
• Growth inhibition
• Morphological changes
• Molecular responses
• Signaling changes
• Resistance patterns

The resulting data can help researchers understand which treatments appear more active against the tested tumor model.

 

The Role of Cancer Organoids

Cancer organoids have become particularly interesting in functional precision oncology.

Organoids are three-dimensional cellular models that can reproduce certain structural and biological features of tissues.

Patient-derived tumor organoids can provide researchers with an experimental system for studying individual tumors outside the body.

One potential application is drug-response testing.

Researchers can expose organoids to different therapeutic agents and compare their responses.

For example, a laboratory study might evaluate several treatment options and determine whether a tumor model demonstrates:

• Strong sensitivity
• Partial sensitivity
• Limited response
• Resistance

This information may provide useful biological insights that complement genomic analysis.

However, organoid models are not perfect replicas of tumors in patients. Their limitations must be considered when interpreting experimental results.

 

Functional Precision Oncology and Drug Resistance

One of the most important potential applications of functional testing is understanding treatment resistance.

Cancer cells can develop resistance through multiple mechanisms.

These may include:

• Secondary genetic alterations
• Activation of alternative signaling pathways
• Changes in cell state
• Drug efflux mechanisms
• Tumor microenvironment interactions
• Cellular plasticity
• Clonal evolution

A tumor that initially responds to therapy may later become resistant.

Functional testing can potentially help researchers investigate these changes by comparing treatment responses before and after therapy or by studying models derived from resistant disease.

This could support the development of strategies to overcome resistance.

 

Testing Combination Therapies

Cancer treatment frequently involves combinations of therapies.

However, identifying effective combinations can be challenging.

Two drugs that appear promising individually may not necessarily work effectively together.

In some circumstances, combining therapies can produce:

• Synergistic effects
• Additive effects
• No meaningful additional benefit
• Increased toxicity

Functional models can provide a platform for experimentally evaluating potential combinations.

Researchers can test different treatment combinations and compare their effects on tumor models.

This could be particularly valuable in cancers where standard treatment options are limited or resistance develops rapidly.

 

Functional Precision Oncology and Tumor Heterogeneity

Tumors are not made up of identical cancer cells.

Different populations of cells can coexist within the same tumor.

This phenomenon is known as intratumoral heterogeneity.

Some cells may be highly sensitive to treatment, while others may survive and eventually contribute to disease progression or recurrence.

Functional approaches may help researchers investigate this complexity.

By studying different tumor-derived populations or models, researchers can explore questions such as:

• Which cancer cell populations are treatment-sensitive?
• Which populations survive therapy?
• What biological mechanisms allow resistant cells to persist?
• Can combination therapies target multiple tumor populations?
• How does tumor evolution affect treatment response?

Understanding heterogeneity is essential for developing more durable cancer therapies.

 

The Importance of Functional Precision Oncology in Rare Cancers

Rare cancers can present significant treatment challenges.

Because fewer patients have a particular rare cancer, clinical trials may be limited, and established treatment pathways may not be as extensive as those available for more common cancers.

Functional testing could provide an additional research strategy for investigating treatment sensitivity in individual tumors.

Patient-derived models may help researchers explore potential therapies when conventional evidence is limited.

Importantly, functional testing should not automatically be interpreted as a guaranteed method for selecting treatment. Clinical validation remains essential.

 

Functional Precision Oncology and AI

Artificial intelligence is increasingly being explored across oncology, and functional precision medicine could benefit from AI-driven analysis.

Functional testing can generate large amounts of experimental data.

For example, researchers may obtain information about:

• Drug sensitivity
• Dose-response relationships
• Cellular morphology
• Molecular changes
• Imaging features
• Growth patterns
• Combination-treatment effects

AI and machine learning methods may help analyze these complex datasets.

Computer vision models can potentially identify subtle cellular changes that are difficult to quantify manually.

Machine learning algorithms may also help researchers identify relationships between:

Molecular profile + functional response + clinical characteristics

Such integrated analysis could eventually support more sophisticated treatment-response prediction.

 

Combining Genomics With Functional Testing

The greatest potential may come from combining multiple forms of information.

Consider a patient whose tumor has been analyzed using genomic sequencing.

The analysis identifies several molecular alterations, but multiple therapeutic options appear potentially relevant.

Functional testing could provide another layer of evidence by examining how the patient's tumor-derived model responds to selected therapies.

Researchers could potentially integrate:

Genomics → Transcriptomics → Proteomics → Functional testing → Clinical data

This multi-dimensional approach could help build a more complete representation of tumor biology.

Rather than asking one test to provide the entire answer, precision oncology can increasingly use multiple evidence streams.

 

Functional Precision Oncology in Clinical Research

Functional precision oncology is also important from a research perspective.

Researchers can use patient-derived models to investigate:

• Mechanisms of drug sensitivity
• Mechanisms of resistance
• New drug combinations
• Treatment sequencing
• Biomarker discovery
• Tumor evolution
• Cancer cell plasticity
• Therapeutic vulnerabilities

These models can help bridge the gap between laboratory discoveries and clinical research.

For pharmaceutical and biotechnology researchers, functional testing may also support the evaluation of new therapeutic candidates.

 

Challenges and Limitations

Despite its promise, functional precision oncology faces important challenges.

Sample Availability

Some patients may not have sufficient tumor material for extensive laboratory testing.

Tumor samples can be limited, particularly when tissue is difficult to obtain.

Time

Cancer treatment decisions can sometimes need to be made quickly.

Developing and testing patient-derived models may take time, depending on the methodology.

For functional testing to become broadly useful in clinical decision-making, workflows must be sufficiently rapid and reliable.

Model Fidelity

No laboratory model perfectly reproduces the complexity of a human tumor.

A model may capture some tumor characteristics while failing to reproduce others.

For example, certain models may not fully preserve:

• Immune interactions
• Stromal components
• Blood supply
• Tissue architecture
• Systemic drug exposure

Standardization

Different laboratories may use different methods for developing models and measuring treatment response.

Standardized protocols and validated endpoints are important for generating reproducible results.

Clinical Validation

Perhaps the most important challenge is demonstrating that functional test results actually improve patient outcomes.

A laboratory model showing drug sensitivity does not automatically mean that the patient will respond to that treatment.

Large-scale prospective clinical studies are therefore important.

 

Functional Testing and the Tumor Microenvironment

The tumor microenvironment plays a major role in cancer progression and therapy response.

Cancer cells interact with:

• Immune cells
• Fibroblasts
• Endothelial cells
• Extracellular matrix
• Signaling molecules

These interactions can influence treatment resistance.

Some functional models attempt to preserve or recreate parts of this environment.

More advanced experimental systems may incorporate multiple cellular components to study how interactions influence therapeutic response.

This is an important direction because cancer cells do not exist in isolation inside the human body.

 

The Future of Functional Precision Oncology

Functional precision oncology is still an evolving field.

Future advances may improve:

• Speed of functional testing
• Model fidelity
• Automation
• High-throughput drug screening
• Combination therapy testing
• AI-based analysis
• Integration with genomic data
• Clinical validation

Technological progress could make functional testing increasingly sophisticated.

Automated laboratory platforms may allow researchers to evaluate many therapeutic conditions simultaneously.

Advanced imaging and computational methods could provide increasingly detailed measurements of cancer-cell behavior.

At the same time, researchers will need to determine which functional approaches provide clinically meaningful information.

 

From Molecular Data to Functional Evidence

Precision oncology has traditionally placed considerable emphasis on molecular profiling.

This has produced major advances in identifying actionable cancer alterations.

But cancer treatment is ultimately about how a tumor behaves in response to therapy.

Functional precision oncology seeks to bring this concept closer to the center of personalized cancer research.

The approach does not necessarily replace genomic precision medicine.

Instead, it can potentially complement it.

A future precision oncology workflow could involve:

Patient → Tumor profiling → Molecular analysis → Functional testing → Integrated data analysis → Treatment selection → Monitoring → Adaptive treatment

Such a model could help move oncology toward increasingly individualized treatment strategies.

 

Functional Precision Oncology and Personalized Cancer Care

The broader goal of precision oncology is simple:

Give the right treatment to the right patient at the right time.

Achieving that goal requires a detailed understanding of individual tumor biology.

Functional precision oncology provides one potential route toward that objective by asking how a patient's cancer cells behave when challenged with different therapeutic strategies.

As technologies for tumor modeling, drug screening, genomics, and computational analysis continue to advance, functional approaches may become an increasingly important component of cancer research.

However, their clinical role will depend on rigorous validation, standardization, accessibility, and integration with established clinical evidence.

Conclusion

Precision oncology is transforming the way cancer is understood, diagnosed, and treated by moving beyond a one-size-fits-all approach toward personalized cancer care. By combining genomic testing, molecular profiling, targeted therapies, immunotherapy, and advanced clinical research, precision oncology is helping researchers and healthcare professionals develop treatment strategies that are increasingly tailored to the unique characteristics of each patient and tumor.

As cancer research continues to advance in 2027, innovations in precision medicine are expected to create new opportunities for earlier detection, better treatment selection, improved monitoring, and more personalized therapeutic approaches. Continued collaboration among oncologists, researchers, clinicians, healthcare professionals, and industry experts will be essential to translating these advances into meaningful improvements in cancer care.

The future of oncology is increasingly personalized, data-driven, and research-focused. Precision oncology will remain an important area of cancer research as the global scientific community works toward more effective and individualized approaches to cancer treatment.

Frequently Asked Questions (FAQs)

1. What is precision oncology?
Precision oncology is an approach to cancer care that uses information about a patient’s tumor, including genetic and molecular characteristics, to help guide personalized treatment strategies.

2. How does precision oncology differ from traditional cancer treatment?
Traditional treatment approaches may rely primarily on cancer type and stage, while precision oncology incorporates molecular and genomic information to help identify treatments that may be more appropriate for an individual tumor.

3. What role does genomic testing play in precision oncology?
Genomic testing can identify specific genetic alterations and molecular features within a tumor. This information may help healthcare professionals evaluate potential targeted therapies and treatment strategies.

4. Can precision oncology improve cancer treatment outcomes?
Precision oncology has the potential to improve treatment selection by helping identify therapies that are more closely matched to the biological characteristics of a patient's cancer. However, its effectiveness varies depending on the cancer type, available biomarkers, treatment options, and individual patient factors.

5. What technologies are used in precision oncology?
Precision oncology can involve genomic sequencing, molecular profiling, biomarker analysis, liquid biopsy, bioinformatics, artificial intelligence, and other advanced technologies used to understand cancer biology and treatment response.

6. What is the future of precision oncology in 2027?
Future developments are expected to focus on integrating multi-omics data, improving biomarker discovery, advancing targeted and immune-based therapies, and using data-driven approaches to support more individualized cancer treatment.

7. Why is precision oncology important for cancer research?
Precision oncology helps researchers better understand differences between tumors and identify molecular characteristics that may influence cancer development, treatment response, and resistance. This can support the development of more personalized cancer therapies.

8. How can researchers and oncology professionals contribute to advances in precision oncology?
Researchers and oncology professionals can contribute through clinical research, biomarker discovery, genomic studies, clinical trials, multidisciplinary collaboration, and sharing emerging findings with the global cancer research community.

About Oncology Summit-2027

International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027) is an international platform bringing together oncologists, cancer researchers, clinicians, healthcare professionals, academicians, and industry experts to exchange knowledge and explore emerging developments in oncology and cancer care.

The summit will take place March 25–27, 2027, in Osaka, Japan, with opportunities for both in-person and virtual participation. The scientific program will cover important areas of modern oncology, including cancer prevention, diagnosis, treatment, precision oncology, immunotherapy, artificial intelligence, drug development, clinical trials, patient-centered cancer care, cancer survivorship, and emerging therapeutic approaches.

The conference will feature keynote presentations, scientific sessions, oral and poster presentations, panel discussions, networking opportunities, and industry engagement, creating opportunities for participants to share research findings and build international collaborations.

Oncology Summit-2027 aims to encourage meaningful scientific exchange and collaboration across disciplines while highlighting innovative approaches that can contribute to advances in cancer research and patient care.

Conference: International Experts Summit on Oncology & Cancer Care (Oncology Summit-2027)
Date: March 25–27, 2027
Location: Osaka, Japan
Format: Hybrid – In-person & Virtual
Focus: Oncology, Cancer Research & Cancer Care

Why Attend Oncology Summit-2027?

• Present your latest oncology research to an international audience.
• Learn about emerging developments in cancer diagnosis and treatment.
• Connect with oncologists, researchers, clinicians, and healthcare professionals.
• Explore developments in precision oncology, immunotherapy, AI, and targeted therapies.
• Participate in scientific discussions and knowledge-sharing sessions.
• Build international academic and professional collaborations.
• Explore opportunities for oral, poster, and virtual presentations